Program
acoramidis
Also written as “Acoramidis”, “Acoramidis (AG10)” and “AG10”.
Its studies are mostly in Amyloid Neuropathies, Familial · Amyloidosis, Hereditary, Transthyretin-Related · Amyloidosis, led by 3 companies.
Drug pageAcoramidis: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBioits history only | 114 open or running | phase 4since Jul 6, 2026 | Sep 18, 2017 | Apr 15, 2028phase 3 · NCT04988386 |
| AstraZenecaits history only | 31 open or running | phase 4since Dec 15, 2025 | Nov 6, 2020 | Mar 31, 2028phase 4 · NCT07306949 |
| Bayerits history only | 11 open or running | phase 4since Dec 11, 2025 | Dec 11, 2025 | Sep 17, 2027phase 4 · NCT07298044 |
Also a collaborator on its studies: Celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 18, 2017.
- May 11, 2018Phase 2 study in Amyloid Neuropathies, FamilialBridgeBio · NCT03536767 · 47 enrolled · United States
- Feb 27, 2019Phase 3 study in AmyloidosisBridgeBio · NCT03860935 · 632 enrolled · United States, Australia, Belgium and more
- Dec 9, 2019Named acoramidisINNProposed as its International Nonproprietary Name in WHO's List 122
- May 22, 2020Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04418024 · United States
- Nov 6, 2020AstraZeneca’s first study: phase 3 study in Symptomatic Transthyretin Amyloid CardiomyopathyNew to AstraZenecaAstraZeneca · NCT04622046 · 25 enrolled · Japan
- Feb 19, 2021Phase 1 study in AmyloidosisBridgeBio · NCT04769479 · 14 enrolled · United Kingdom
- Apr 29, 2021Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04882735
- Jul 1, 2021Phase 1 study in HealthyAstraZeneca · NCT04958135 · 18 enrolled · United States
- Jul 13, 2021Phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04988386 · 389 enrolled · United States, Australia, Belgium and more
- Aug 5, 2024Phase 3 study in AmyloidosisBridgeBio · NCT06563895 · 587 planned · United States, Argentina, Australia and more
- Aug 7, 2025Phase 3 study in Amyloidosis, FamilialBridgeBio · NCT07116473 · 250 planned
- Dec 11, 2025Bayer’s first study: phase 4 study in Transthyretin Amyloid CardiomyopathyNew to BayerBayer · NCT07298044 · 50 planned · Austria, Belgium, Germany and more
- Dec 15, 2025Phase 4 study in Transthyretin-type Cardiac AmyloidosisAstraZeneca · NCT07306949 · 200 planned · Japan
- Jul 6, 2026Phase 4 study in AmyloidosisBridgeBio · NCT07695701 · 150 planned · United States
- Oct 14, 2026Phase 2 study terminatedStudy stoppedNCT03536767 · “Study ended by the sponsor due to meeting Study Objectives”
Ahead
- Sep 17, 2027Primary completion: phase 4 study in Transthyretin Amyloid CardiomyopathyBayer · NCT07298044
- Mar 31, 2028Primary completion: phase 4 study in Transthyretin-type Cardiac AmyloidosisAstraZeneca · NCT07306949
- Apr 15, 2028Primary completion: phase 3 study in Amyloid Neuropathies, FamilialBridgeBio · NCT04988386
- Aug 2030Primary completion: phase 4 study in AmyloidosisBridgeBio · NCT07695701
TargetBeta
“Transthyretin stabiliser; Transthyretin stabiliser”ChEMBL 37, by rule
Other programs on TTR
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07695701Amyloidosis · United States | 4 | Recruiting | BridgeBio | Aug 2030 | 150 |
| NCT07306949Transthyretin-type Cardiac Amyloidosis · Japan | 4 | Recruiting | AstraZeneca | Mar 31, 2028 | 200 |
| NCT07298044Transthyretin Amyloid Cardiomyopathy · Austria, Belgium, Germany and more | 4 | Recruiting | Bayer | Sep 17, 2027 | 50 |
| NCT07116473Amyloidosis, Familial | 3 | Not yet recruiting | BridgeBio | Nov 2037 | 250 |
| NCT06563895Amyloidosis · United States, Argentina, Australia and more | 3 | Recruiting | BridgeBio | Oct 2031 | 587 |
| NCT04988386Amyloid Neuropathies, Familial · United States, Australia, Belgium and more | 3 | Active, not recruiting | BridgeBio | Apr 15, 2028 | 389 |
| NCT04958135Healthy · United States | 1 | Completed | AstraZeneca | Aug 4, 2021 | 18 |
| NCT04882735Amyloid Neuropathies, Familial | 3 | Withdrawn | BridgeBio | Sep 2026 | 0 |
| NCT04769479Amyloidosis · United Kingdom | 1 | Completed | BridgeBio | Aug 4, 2021 | 14 |
| NCT04622046Symptomatic Transthyretin Amyloid Cardiomyopathy · Japan | 3 | Completed | AstraZeneca | Nov 8, 2023 | 25 |
| NCT04418024Amyloid Neuropathies, Familial · United States | 3 | Withdrawn | BridgeBio | Mar 31, 2024 | 0 |
| NCT03860935Amyloidosis · United States, Australia, Belgium and more | 3 | Completed | BridgeBio | May 11, 2023 | 632 |
| NCT03536767Amyloid Neuropathies, Familial · United States | 2 | Terminated | BridgeBio | Sep 15, 2025 | 47 |
| NCT03458130Familial ATTR-CM (ATTRm-CM, or FAC) · United States | 2 | Completed | BridgeBio | Oct 5, 2018 | 49 |
| NCT03294707Amyloid Neuropathies, Familial · United States | 1 | Completed | BridgeBio | Feb 5, 2018 | 56 |
How it is read
Names in the registry
- “Acoramidis”, 6 entries
- “Acoramidis (AG10)”, 2 entries
- “AG10”, 2 entries
- “acoramidis”, 2 entries
- “Acoramidis (AG10) oral tablet”, 1 entry
Conditions, from the studies’ own filings
- Amyloid Neuropathies, Familial, 5 studies
- Amyloidosis, Hereditary, Transthyretin-Related, 4 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.